RU2016119746A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016119746A3 RU2016119746A3 RU2016119746A RU2016119746A RU2016119746A3 RU 2016119746 A3 RU2016119746 A3 RU 2016119746A3 RU 2016119746 A RU2016119746 A RU 2016119746A RU 2016119746 A RU2016119746 A RU 2016119746A RU 2016119746 A3 RU2016119746 A3 RU 2016119746A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306475 | 2013-10-25 | ||
| EP13306475.8 | 2013-10-25 | ||
| PCT/EP2014/072915 WO2015059302A1 (en) | 2013-10-25 | 2014-10-24 | Stable formulation of insulin glulisine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016119746A RU2016119746A (ru) | 2017-11-30 |
| RU2016119746A3 true RU2016119746A3 (enExample) | 2018-06-04 |
| RU2691059C2 RU2691059C2 (ru) | 2019-06-10 |
Family
ID=49552301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016119746A RU2691059C2 (ru) | 2013-10-25 | 2014-10-24 | Стабильный состав инсулина глулизин |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20150119323A1 (enExample) |
| EP (1) | EP3060240A1 (enExample) |
| JP (1) | JP6525987B2 (enExample) |
| KR (1) | KR20160074562A (enExample) |
| CN (1) | CN105705161A (enExample) |
| AR (1) | AR098168A1 (enExample) |
| AU (1) | AU2014338863A1 (enExample) |
| BR (1) | BR112016008736A2 (enExample) |
| CA (1) | CA2928320A1 (enExample) |
| CL (1) | CL2016000950A1 (enExample) |
| HK (1) | HK1225613A1 (enExample) |
| IL (1) | IL245109A0 (enExample) |
| MX (1) | MX2016005395A (enExample) |
| PH (1) | PH12016500720A1 (enExample) |
| RU (1) | RU2691059C2 (enExample) |
| SG (2) | SG11201602939QA (enExample) |
| TW (1) | TW201605489A (enExample) |
| WO (1) | WO2015059302A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201607918D0 (en) * | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| CA3094237A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| FR3083700B1 (fr) * | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
| AR131148A1 (es) * | 2022-11-26 | 2025-02-19 | Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» | Composiciones de insulina de acción rápida (variantes de las mismas) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| AR012894A1 (es) | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| CN102083419A (zh) * | 2008-07-01 | 2011-06-01 | 日东电工株式会社 | 包含表面被覆了的微粒的医药组合物 |
| WO2011003822A2 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Insulinzubereitungen enthaltend methionin |
| AU2010277559B2 (en) * | 2009-07-31 | 2016-08-11 | Sanofi-Aventis Deutschland Gmbh | Prodrugs comprising an insulin linker conjugate |
| CA2780460C (en) * | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| CN101912600B (zh) * | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| US20130011378A1 (en) * | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| KR20140043438A (ko) * | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
| WO2014076423A1 (fr) * | 2012-11-13 | 2014-05-22 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| SG11201604706TA (en) * | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
-
2014
- 2014-10-23 TW TW103136573A patent/TW201605489A/zh unknown
- 2014-10-23 AR ARP140103985A patent/AR098168A1/es unknown
- 2014-10-24 SG SG11201602939QA patent/SG11201602939QA/en unknown
- 2014-10-24 CA CA2928320A patent/CA2928320A1/en not_active Abandoned
- 2014-10-24 CN CN201480058603.5A patent/CN105705161A/zh active Pending
- 2014-10-24 RU RU2016119746A patent/RU2691059C2/ru not_active IP Right Cessation
- 2014-10-24 US US14/523,842 patent/US20150119323A1/en not_active Abandoned
- 2014-10-24 AU AU2014338863A patent/AU2014338863A1/en not_active Abandoned
- 2014-10-24 WO PCT/EP2014/072915 patent/WO2015059302A1/en not_active Ceased
- 2014-10-24 SG SG10201803430SA patent/SG10201803430SA/en unknown
- 2014-10-24 HK HK16113873.7A patent/HK1225613A1/zh unknown
- 2014-10-24 JP JP2016524503A patent/JP6525987B2/ja not_active Expired - Fee Related
- 2014-10-24 BR BR112016008736A patent/BR112016008736A2/pt not_active Application Discontinuation
- 2014-10-24 EP EP14789560.1A patent/EP3060240A1/en not_active Withdrawn
- 2014-10-24 KR KR1020167012895A patent/KR20160074562A/ko not_active Withdrawn
- 2014-10-24 MX MX2016005395A patent/MX2016005395A/es unknown
-
2016
- 2016-04-14 IL IL245109A patent/IL245109A0/en unknown
- 2016-04-18 PH PH12016500720A patent/PH12016500720A1/en unknown
- 2016-04-21 CL CL2016000950A patent/CL2016000950A1/es unknown
-
2017
- 2017-10-27 US US15/656,839 patent/US20180036411A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1225613A1 (zh) | 2017-09-15 |
| AR098168A1 (es) | 2016-05-04 |
| CL2016000950A1 (es) | 2016-11-04 |
| SG10201803430SA (en) | 2018-06-28 |
| AU2014338863A1 (en) | 2016-05-19 |
| IL245109A0 (en) | 2016-06-30 |
| RU2691059C2 (ru) | 2019-06-10 |
| EP3060240A1 (en) | 2016-08-31 |
| KR20160074562A (ko) | 2016-06-28 |
| MX2016005395A (es) | 2017-02-28 |
| US20150119323A1 (en) | 2015-04-30 |
| SG11201602939QA (en) | 2016-05-30 |
| RU2016119746A (ru) | 2017-11-30 |
| PH12016500720A1 (en) | 2016-05-30 |
| JP6525987B2 (ja) | 2019-06-05 |
| JP2016539921A (ja) | 2016-12-22 |
| US20180036411A1 (en) | 2018-02-08 |
| CA2928320A1 (en) | 2015-04-30 |
| BR112016008736A2 (pt) | 2017-09-12 |
| WO2015059302A1 (en) | 2015-04-30 |
| CN105705161A (zh) | 2016-06-22 |
| TW201605489A (zh) | 2016-02-16 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201025 |